Ethylphenidate

# Research Output: Ethylphenidate

## Chemical Identity

**Verified from PubChem CID 3080846 and cross-referenced chemical databases:**

- **Molecular Formula:** C₁₅H₂₁NO₂ [Ref 33] — confirmed from PubChem [Ref 33], **NOT present in seed data; this is a seed gap now filled.**
- **Molecular Weight:** 247.33 g/mol [Ref 33] — **NOT present in seed data; now filled.**
- **IUPAC Name:** ethyl 2-phenyl-2-piperidin-2-ylacetate [Ref 33]
- **Systematic Name (seed):** ethyl 2-phenyl-2-piperidin-2-ylacetate — **confirmed correct** [Ref 33]
- **SMILES (racemic):** CCOC(=O)C(c1ccccc1)C2CCCCN2 [Ref 33] — **NOT present in seed data; now filled.**
- **InChIKey:** AIVSIRYZIBXTMM-UHFFFAOYSA-N — **confirmed from PubChem** [Ref 33]
- **PubChem CID:** 3080846 — **NOT present in seed data; now filled.**
- **CAS Number:** 57413-43-1 [Ref 33] — **NOT present in seed data; now filled.**

**Seed Data Discrepancies:**
- Seed data left SMILES, molecular formula, molecular weight, InChIKey, and PubChem CID blank. All have now been confirmed from primary sources. No contradictions found — only gaps filled.

**Stereochemistry:**
Ethylphenidate has two chiral centers, yielding four stereoisomers grouped into two racemates: threo (d,l) and erythro (d,l). As a research chemical/NPS product, EPH is typically sold as the racemic threo mixture (dl-threo-ethylphenidate) [Ref 1]. The pharmacologically active enantiomer is (+)-threo (d-threo) ethylphenidate [Ref 1, Ref 2]. The l-threo (levo) enantiomer is biologically inactive [Ref 2]. This mirrors the stereochemical pharmacology of methylphenidate (MPH), where only d-threo-MPH is active.

**Physical Properties:**
No published melting point or aqueous solubility data were found in peer-reviewed literature. EPH is typically encountered as a white crystalline powder or hydrochloride salt. CAS 57413-43-1 applies to the racemic free base form.

---

## Pharmacology

### Mechanism of Action

Ethylphenidate is a monoamine reuptake inhibitor. Its primary mechanism is competitive inhibition of the dopamine transporter (DAT), with secondary, weaker activity at the norepinephrine transporter (NET), and negligible serotonin transporter (SERT) activity [Ref 1, Ref 2, Ref 5, Ref 6].

**Transporter Inhibition Data (d-EPH):**
- **DAT IC₅₀ = 27 nM** for (+)-threo-ethylphenidate — approximately 13.6× more potent than cocaine (IC₅₀ 367 nM) at DAT [Ref 1]
- (-)-threo-ethylphenidate DAT IC₅₀ = 1,730 nM (inactive enantiomer) [Ref 1]
- **DAT/NET selectivity:** d-EPH shows markedly greater selectivity for DAT over NET compared to d-MPH [Ref 2, Ref 5]. d-MPH exhibits approximately equipotent inhibition at DAT and NET; d-EPH preferentially inhibits DAT [Ref 5]
- **NET:** d-EPH is a less potent NET inhibitor than d-MPH [Ref 2]; exact IC₅₀ not reported in available abstracts
- **SERT:** Negligible activity reported for MPH class in vitro; EPH-specific SERT Ki not reported in available data

**Luethi et al. 2018 [Ref 6]** (Neuropharmacology) conducted the most comprehensive in vitro pharmacological profiling of MPH-based designer drugs including EPH, confirming DAT selectivity. Full quantitative data from this paper were not extractable from available abstract; the open-access PDF was not machine-readable in this session. The paper is recommended as a primary source for complete Ki/IC₅₀ tables.

**FLAG for generation agent:** Full pharmacological binding tables from Luethi et al. 2018 [Ref 6] should be referenced; specific NET/SERT Ki values for EPH from that paper were not available in abstract form. The paper is open access at: https://researchonline.ljmu.ac.uk/id/eprint/6945/1/MPH_accepted_August_2017_Neuropharmacology.pdf

### Downstream Neurochemical Effects

By blocking DAT, EPH prevents dopamine reuptake into the presynaptic terminal, increasing synaptic dopamine concentrations in the nucleus accumbens (reward/euphoria), striatum (motor), and prefrontal cortex (cognition) [Ref 8]. Repeated EPH exposure in adolescent mice produced elevated deltaFosB expression in the dorsal striatum, nucleus accumbens, and prefrontal cortex — a marker associated with increased addiction vulnerability [Ref 8]. Conditioned place preference was demonstrated even at non-stimulatory doses (5 mg/kg i.p.) in mice, indicating rewarding properties at sub-stimulant exposures [Ref 8].

Repeated EPH (15 mg/kg × 8 days) decreased spatial cognitive performance on the Barnes maze in adolescent male mice, without corresponding changes in mature BDNF expression, suggesting a dissociation between cognitive impairment and neurotrophic factor changes [Ref 8].

### Pharmacokinetics

**No formal human PK studies of EPH as a standalone substance exist.** All available human PK data for EPH derive from studies of MPH+ethanol interactions where EPH is a transesterification metabolite (see Metabolism section below). Formal PK parameters (Cmax, Tmax, AUC, bioavailability, half-life) for orally self-administered EPH have not been published.

**Animal (equine) PK data [Ref 17]:**
- Knych et al. 2018 studied IV (10 mg and 40 mg) and oral (40 mg) EPH administration in horses (n=12)
- Serum EPH concentrations fell below detectable levels by 8h (IV 10 mg), 18h (IV 40 mg), and 12h (oral 40 mg) post-administration
- Ritalinic acid was non-detectable at 72h post-dose
- GI adverse effects were noted in all dose groups
- No significant stimulatory behavior or heart rate changes were observed at the doses studied (⚠ horse data — species limitation noted)

**Metabolism:**
EPH is metabolized primarily by hydrolysis of its ethyl ester moiety by carboxylesterases, principally CES1, to yield **ritalinic acid** (alpha-phenyl-alpha-(2-piperidyl)acetic acid) as the primary metabolite [Ref 7]. This is the same primary metabolic fate as MPH. Minor pathways include aromatic hydroxylation and conjugation [Ref 7].

**Critical Metabolic Interaction — MPH + Ethanol:**
When methylphenidate is co-ingested with ethanol, hepatic and intestinal CES1 (carboxylesterase 1) enantioselectively transesterifies l-MPH with ethanol to produce **l-ethylphenidate** [Ref 3, Ref 4, Ref 7]. This process:
- Was first confirmed in humans by Markowitz et al. 1999 [Ref 15] in postmortem blood of MPH+alcohol overdose victims
- Simultaneously increases plasma d-MPH Cmax by 40–100% by competitive inhibition of CES1-mediated l-MPH hydrolysis [Ref 4]
- Produces potentiation of subjective effects ("high," "stimulated") statistically significant within the absorption phase [Ref 4]
- Plasma l-EPH concentrations exceeded those of l-MPH in subjects receiving dl-MPH+ethanol [Ref 3]
- l-EPH formed is biologically inactive; but d-MPH elevation is the primary euphoriant/abuse liability amplifier [Ref 3, Ref 4, Ref 5]
- Patrick et al. 2014 [Ref 5] established d-EPH (as a direct-acting drug) as a "selective dopaminergic agonist" given its DAT >> NET selectivity, with implications for ADHD pharmacotherapy and abuse liability

**Bioavailability and Oral Route:**
No published human bioavailability data for orally administered EPH as a standalone drug. MPH oral bioavailability is ~30% for d-MPH due to first-pass CES1 hydrolysis; EPH would be expected to have higher bioavailability by inference (less susceptible to CES1 hydrolysis due to ethyl vs. methyl ester), but this is structural inference, not published data.

---

## History

**Discovery/First Synthesis:**
EPH was not identified as a research compound until its role as a metabolite of MPH+ethanol co-ingestion became apparent. Markowitz et al. (1999) [Ref 15] provided the first human detection — EPH was found in postmortem blood of two MPH overdose victims who had also ingested ethanol. This established the compound's existence as an in vivo human metabolite. Earlier in vitro work using rat liver preparations had predicted EPH formation, but the 1999 paper was the first human confirmation.

The formal synthetic and pharmacological characterization of EPH enantiomers was published by Patrick et al. (2005) [Ref 1] in the *Journal of Medicinal Chemistry*, establishing the DAT IC₅₀ of 27 nM and the differential DAT/NET selectivity compared to MPH.

**Appearance as Novel Psychoactive Substance (NPS):**
EPH appeared on the research chemical/NPS market as an unscheduled stimulant approximately late 2010 or early 2011 [web-retrieved]. It was formally notified as a new substance by the EU Early Warning System (via EMCDDA/FEWS) in 2011 [Ref 21, web-retrieved]. It was marketed as a legal substitute for cocaine and sold under street names including "Gogaine" and "Burst" [UK Gov web-retrieved]. From approximately 2013–2015, EPH became particularly prevalent in Scotland, where it was identified as a substitute stimulant used primarily by existing heroin injectors who also began injecting EPH [Ref 10, Ref 12].

**Regulatory/Prohibition Timeline:**
- Austria: January 1, 2012 — controlled under NPSG (New Psychoactive Substances Act)
- Germany: July 17, 2013 — controlled under Anlage II BtMG (Narcotics Act Schedule II)
- UK: April 10, 2015 — UK Government accepted ACMD advice, Temporary Class Drug Order placed on EPH and 6 other MPH-based NPS [Ref 27]
- UK: June 27, 2016 — TCDO renewed/extended under the Misuse of Drugs Act 1971 (Temporary Class Drug) Order 2016 [Ref 29]
- UK: May 26, 2016 — UK Psychoactive Substances Act 2016 blanket ban came into force; EPH subsequently covered as a psychoactive substance
- Canada: May 5, 2017 — Added to Schedule III of the Controlled Drugs and Substances Act
- USA: November 21, 2024 — DEA placed EPH in Schedule I of the Controlled Substances Act [Ref 28]

---

## Subjective Effects

**Primary Source:** Soussan & Kjellgren (2015) [Ref 26] — the only dedicated published study of EPH subjective effects — analyzed self-reports from international internet drug forums. Seven overarching themes identified:

1. **Compulsive Redosing and Addiction:** Compulsive redosing was a dominant theme; users described an overwhelming urge to re-administer, leading to binge patterns. This matches the seed data's listing of "compulsive redosing urge" as an expected effect.

2. **Impacts on Mental State:** Effects included both pleasurable outcomes (euphoria, cognitive enhancement, heightened focus, increased motivation) and adverse outcomes (indecisiveness, anxiety, cognitive fragmentation, paranoia at high doses).

3. **Bodily Agitation:** Users reported increased body temperature, elevated heart rate, blood pressure, profuse sweating, and muscle tension. Some described unpleasant physical side effects at higher doses including jaw clenching (bruxism) and jaw tension.

4. **Increased Sociableness:** EPH was described as a social lubricant — enhancing communication, intimacy, social skills, and openness. This maps to sociability-enhancement and communication-enhancement effects.

5. **Administration Routes:** Primary routes reported in the community included insufflation (intranasal), oral ingestion, and in the Scottish NPS-injecting community, intravenous injection. The oral route was noted as producing a more delayed, less intense but longer effect; insufflation produced faster onset.

6. **Diverse Evaluations Based on Intention:** Recreational users (seeking euphoria/stimulation) contrasted with nootropic users (seeking cognitive enhancement, productivity); the latter reported using lower doses.

7. **Safety and Precaution:** Many users expressed awareness of risks, particularly cardiovascular strain and the compelling compulsive redosing pattern.

**Duration (user-reported, from forum analysis):**
Users described typical effects lasting several hours, with oral administration producing longer duration effects. The seed data range of 4–7 hours (oral) and 2–6 hours (rectal) are consistent with the class pharmacology but not directly confirmed by any controlled human study.

**Animal Data:**
In adolescent male mice, acute EPH exposure induced hyperlocomotion at 15 mg/kg i.p. but not at 5 mg/kg i.p. — indicating a dose-dependent locomotor stimulant effect [Ref 8]. Conditioned place preference was observed at 5 mg/kg, demonstrating rewarding properties at sub-stimulatory doses.

**FLAG:** No controlled human clinical studies of EPH subjective effects, dose-response curves, or pharmacodynamics exist. All human effects data derives from internet forum analysis [Ref 26] or forensic case reports [Ref 9, Ref 10, Ref 14].

---

## Safety & Toxicity

### Fatality Data

Multiple published case series document EPH-related deaths:

**Parks et al. 2015 [Ref 10]** — Review of 19 cases in East and West Scotland (July 2013 – December 2014):
- Ages 20–54 (median 37); predominantly male (n=14); predominantly East Scotland/Edinburgh (n=16)
- EPH postmortem femoral blood concentrations: 0.008–2+ mg/L (median 0.25 mg/L, mean 0.39 mg/L)
- Drug toxicity was sole or contributory factor in 10/19 cases
- EPH specifically named in cause of death in 5 cases
- Chronic IV drug use named in 2 cases; IV drug use complications/infections in 6 cases
- Co-detected substances: benzodiazepines (n=15), opiates (n=11, 4 with 6-MAM), methadone (n=8)
- IV route of administration was common

**Maskell et al. 2016 [Ref 9]** — 7 fatalities (February 2013 – January 2015), UK (England):
- All male, ages 23–49 (median 25)
- EPH concentrations 0.026–2.18 mg/L in postmortem femoral blood
- Only 1 case with EPH as sole detected drug; EPH toxicity sole cause of death in this case
- Remaining cases: at least 2 other drug classes present (benzodiazepines, heroin, methadone, antipsychotics, other NPS)
- Causes of death: 4 mixed drug toxicity, 2 hanging, 1 EPH toxicity

**Single German fatality:** Maskell et al. 2016 [Ref 9] notes there was "a single case report of a death associated with ethylphenidate in Germany" prior to their case series; however, the primary German publication was not identified in this search.

**Postmortem Reference Range:**
Based on Parks et al. [Ref 10] and Maskell et al. [Ref 9], femoral blood concentrations of 0.008–2+ mg/L have been documented in fatality cases. The highest single-EPH case involved 2.18 mg/L (Maskell) and 2 mg/L (Parks). However, most deaths involved polydrug combinations, making EPH-specific toxic thresholds uncertain. **FLAG: No established LD50, LOAEL, or therapeutic index for EPH in humans exists in the published literature.**

### Case Reports of Adverse Events

**Roy et al. 2020 [Ref 11]** — 2 French case reports of serious complications from IV EPH injection:
- Serious vascular damage and tissue injury reported
- Abstract not available in full; complication types not fully specifiable from available data
- ⚠ **FLAG: Full text not retrievable; generation agent should attempt to access doi:10.1097/JCP.0000000000001167 for complete clinical detail**

**Barceló et al. 2017 [Ref 14]** — Emergency Department case:
- Patient presented with acute intoxication; EPH, ritalinic acid, 5-MAPB, 5-APB, 5-EAPB identified in urine, serum, and hair
- Hair analysis confirmed repeated prior use
- Signs at ED presentation consistent with acute stimulant intoxication

**Robertson 2017 [Ref 13]** — Prolonged mental health effects beyond cessation:
- Published in *Addiction*; abstract not available in full in this search
- Documents persistence of psychiatric symptoms after stopping EPH
- ⚠ **FLAG: Full text not retrievable; generation agent should attempt to access doi:10.1111/add.13630**

### Injection-Related Harms

Intravenous injection of EPH powder preparations was extensively documented in Scotland:
- Lafferty et al. 2016 [Ref 12] documented a surge in IV EPH injecting in Lothian (April 2014 – March 2015)
- McAuley et al. 2019 [Ref 30] documented an HIV outbreak among PWID in Greater Glasgow and Clyde (2015); IV NPS use including EPH was identified as a major risk factor in the largest UK HIV outbreak among PWID in 30 years
- IV EPH use was particularly prevalent among existing heroin injectors who began using EPH as a cocaine substitute
- EPH powder is not formulated for IV use; injection carries risks of particulate emboli, vascular damage, abscess, and bloodborne virus transmission

### Cardiovascular Risks

Users in Soussan & Kjellgren 2015 [Ref 26] consistently reported: increased heart rate, elevated blood pressure, and increased body temperature. These are expected class effects of DAT/NET inhibitors and are consistent with noradrenergic stimulation. Abnormal heartbeat (arrhythmia risk) was included in seed effect profile with community consensus provenance.

### Psychological Risks

- Compulsive redosing with high addiction potential documented in user reports [Ref 26]
- deltaFosB upregulation (addiction vulnerability marker) in striatum/NAc/PFC with repeated use in adolescent mice [Ref 8]
- Prolonged psychiatric effects after cessation documented [Ref 13]
- Cognitive impairment (spatial learning) documented in repeated EPH adolescent mouse model [Ref 8]

---

## Harm Reduction

**Testing:** EPH as a standalone powder is not reliably distinguished from MPH by appearance. Reagent testing (Marquis, Simon's, Mecke) and more reliably by GC-MS, LC-MS/MS, or NMR. Fourier-transform infrared spectroscopy (FTIR) and mass spectrometry are recommended for formal identification [Ref 14, Ref 31, Ref 32]. Drug checking services with quantitative analysis are recommended.

**Compulsive Redosing:** The dominant harm reported by community users was the compulsive, binge-inducing nature of EPH. Harm reduction messaging should prominently address the compulsive redosing risk [Ref 26].

**Injection (Absolute Contraindication):** EPH is not formulated for intravenous use. IV administration of EPH powder is associated with serious vascular complications [Ref 11], HIV transmission [Ref 30], and polydrug-related fatality [Ref 10]. The only evidence-based harm reduction recommendation is to avoid IV use entirely.

**Dose and Titration:** No published dose-response data exists for human EPH. All dose data is community-derived. Users should start with the lowest possible dose to assess individual sensitivity.

**Polydrug Risk:** The majority of EPH-related fatalities involved co-administration with benzodiazepines, opiates, and/or methadone [Ref 9, Ref 10]. Combination with CNS depressants (benzodiazepines, opioids, alcohol) substantially increases overdose risk.

**Contraindications from Literature:**
- History of cardiovascular disease or hypertension (class contraindication: stimulant)
- Co-administration with MAOIs (hypertensive crisis risk by class inference)
- Co-administration with tramadol (see Interactions — flagged as potentially lethal in seed data, mechanism may involve lowered seizure threshold and serotonergic interaction)
- Co-administration with MDMA (hyperthermia, cardiovascular strain, possible serotonergic interaction)

**Emergency Response:**
For suspected EPH overdose, supportive treatment is the standard of care (no antidote exists). Benzodiazepines may be used for seizures and agitation. Hyperthermia management is critical. Clinicians should screen for co-ingested substances given high prevalence of polydrug use. Standard immunoassay screens may not detect EPH; targeted LC-MS/MS is required [Ref 14, Ref 31, Ref 32].

---

## Tolerance & Dependence

**Tolerance:**
No direct published studies of tolerance development in human EPH users. By class analogy with MPH and stimulants acting on DAT:
- Tolerance to locomotor stimulant effects develops rapidly with repeated use (sensitization may also occur for some effects)
- The seed data values (tolerance builds with prolonged/repeated use; half-life of tolerance 5 days; full reset 1.5 weeks; cross-tolerance with dopaminergic stimulants) are **not confirmed by published EPH-specific studies**; they represent class-based inference from MPH and stimulant literature
- **FLAG:** Tolerance data should be flagged as community-consensus/structural inference; no published EPH human tolerance studies found

**Dependence:**
- Compulsive redosing documented in community user reports [Ref 26]
- deltaFosB upregulation (marker of addiction vulnerability) in striatal/NAc/PFC circuits with repeated EPH in mice [Ref 8]
- Conditioned place preference at sub-stimulatory doses in mice [Ref 8]
- Prolonged psychiatric effects after cessation [Ref 13]
- Seed data characterizes dependence as "moderate" physical and psychological with "moderately addictive" potential and high abuse liability — this is broadly supported by animal data [Ref 8] and user reports [Ref 26], but not by formal clinical dependence studies
- **FLAG:** Physical and psychological dependence severity ratings should be flagged as community/animal-inference; no human clinical dependence study exists

---

## Interactions

### Alcohol (Ethanol)

**CRITICAL DISCREPANCY WITH SEED DATA:** The seed data lists the alcohol interaction as "unknown." This is **incorrect based on published literature.**

The ethanol-EPH interaction is bidirectional and well-studied:
1. **When EPH is taken as standalone + alcohol co-ingested:** Ethanol inhibits CES1-mediated hydrolysis of EPH, potentially elevating EPH blood concentrations and prolonging its duration. This has not been directly studied for EPH-standalone+ethanol, but the mechanism is established for the analogous MPH+ethanol interaction [Ref 3, Ref 4, Ref 7].
2. **When MPH is taken + alcohol co-ingested:** EPH is formed endogenously via CES1 transesterification, producing a novel pharmacologically active metabolite [Ref 15, Ref 7].
3. Combined stimulant+alcohol use carries cardiovascular risks (elevated heart rate, blood pressure from the stimulant amplified by EPH formation).

**FLAG for generation agent:** The alcohol interaction should be re-rated from "unknown" to at least "caution" or "dangerous," given the well-established pharmacokinetic interaction mechanism (CES1 inhibition, EPH formation from MPH, and the general cardiovascular risks of combining stimulants with alcohol). This warrants editorial review of the interaction severity rating.

### Tramadol

Seed data rates as "lethal." Tramadol has mild serotonin and norepinephrine reuptake inhibition activity, as well as mu-opioid agonism. The interaction mechanism with EPH (a DAT/NET inhibitor) is not definitively established in published literature. Multiple EPH fatality cases involved co-administration of multiple drugs; tramadol is a Schedule IV CNS depressant with serotonergic activity that could theoretically contribute to serotonin-related toxicity in combination with a stimulant. Additionally, both EPH and tramadol lower the seizure threshold in susceptible individuals. Parks et al. 2015 [Ref 10] and Maskell et al. 2016 [Ref 9] document EPH polydrug deaths with various co-administered substances, but no specific tramadol+EPH combination fatality was extracted from available abstracts. **FLAG:** The "lethal" rating for tramadol+EPH is not confirmed by a published pharmacological interaction study specific to this combination; it appears to be a precautionary rating. Editorial review recommended.

### MDMA

Seed data rates as "dangerous." MDMA causes release of serotonin, dopamine, and norepinephrine. EPH inhibits DAT/NET reuptake. Combined use would be expected to produce additive/synergistic cardiovascular stimulation (tachycardia, hypertension), elevated body temperature, and potentially hyperthermia. MDMA's serotonin-releasing effects could compound cardiovascular strain. No published clinical or case report data specific to EPH+MDMA interaction was identified in this search. The "dangerous" rating is plausible based on pharmacological class effects but is not confirmed by a published case report or clinical study. **FLAG:** Classification as "dangerous" is reasonable based on pharmacological inference but should be labeled as such.

---

## Legal Status

| Jurisdiction | Status | Date | Basis |
|---|---|---|---|
| Austria | Illegal (NPSG) | January 1, 2012 | New Psychoactive Substances Act |
| Germany | Anlage II BtMG (Schedule II) | July 17, 2013 | German Narcotics Act |
| United Kingdom | Banned (PSA 2016) | May 26, 2016 | Psychoactive Substances Act 2016 blanket ban; preceded by TCDO from April 10, 2015 [Ref 27, Ref 29] |
| Canada | CDSA Schedule III | May 5, 2017 | Controlled Drugs and Substances Act |
| United States | Schedule I (DEA) | November 21, 2024 | Controlled Substances Act [Ref 28] |
| Australia | Analogue control | Ongoing | Captured as MPH analogue under existing legislation (no specific scheduling found) |
| Sweden | Controlled | — | Referenced in ACMD TCDO documentation as controlled |
| Denmark | Controlled | — | Referenced in ACMD TCDO documentation as controlled |
| China | Controlled | — | Referenced in ACMD TCDO documentation |
| Poland | Controlled | — | Referenced in ACMD TCDO documentation |

**FLAG:** Australia-specific scheduling instrument and date were not confirmed in a primary government source; web-retrieved information states EPH is "captured under drug legislation as an analogue of methylphenidate." This should be verified against the Therapeutic Goods Administration's Poisons Standard or state-level legislation.

---

## Clinical Trials

**No registered clinical trials for ethylphenidate were found on ClinicalTrials.gov.** [Confirmed via search, 0 results.]

EPH has no approved medical use in any jurisdiction. No Phase I, II, or III human pharmacology studies for EPH have been published.

---

## Community Feedback Analysis

**No community feedback was submitted in Part A2 of the brief.** No feedback items to evaluate.

---

## Gaps & Flags

### Data Gaps

1. **No human PK studies** for EPH as a standalone substance — Tmax, Cmax, AUC, bioavailability, half-life, protein binding, Vd are all unknown from published sources. Dose/duration seed data should be flagged as community-consensus only.

2. **No human dose-response studies** — all dose ranges in seed data (oral and rectal) derive from community consensus; no controlled study has established safe or effective dose ranges.

3. **No LD50 data** for EPH in any species — exact toxic dose unknown as stated in seed data.

4. **No published EPH tolerance studies** in humans — tolerance/half-life/reset values in seed data are inferred from stimulant class data.

5. **No melting point or solubility data** found in published literature.

6. **Full abstracts unavailable** for Robertson 2017 [Ref 13] (prolonged psychiatric effects) and Roy et al. 2020 [Ref 11] (IV complications case reports) — generation agent should access these full texts.

7. **Luethi et al. 2018 [Ref 6]** complete quantitative binding data (Ki tables) were not extractable from the available abstract — the open-access PDF should be consulted for specific DAT/NET/SERT values for EPH.

8. **German single fatality case report** referenced in Maskell 2016 [Ref 9] — specific German publication not identified; may require German-language literature search.

9. **SMILES in seed data was blank** — now filled: CCOC(=O)C(c1ccccc1)C2CCCCN2 (racemic). Generation agent should update the DB record.

10. **PubChem CID in seed data was blank** — now filled: 3080846. Molecular formula (C₁₅H₂₁NO₂) and MW (247.33) also blank in seed — now confirmed.

### Safety-Critical Flags

11. ⚠ **ALCOHOL INTERACTION INCORRECTLY RATED AS "UNKNOWN"** in seed data. Published literature demonstrates a well-characterized pharmacokinetic interaction between EPH and ethanol via CES1. The interaction should be re-rated. This is a safety-critical error in the seed data.

12. ⚠ **TRAMADOL INTERACTION RATED AS "LETHAL"** — not confirmed by a specific published case report or interaction study for EPH+tramadol specifically. The rating appears precautionary. Should be reviewed editorially and labeled as pharmacological inference.

13. ⚠ **Postmortem EPH blood concentrations** (range 0.008–2+ mg/L) are available from Scottish case series, but interpretation is confounded by polydrug use in nearly all cases. A definitive single-EPH toxic threshold has not been established.

14. ⚠ **IV injection of EPH** is associated with HIV transmission (Scottish outbreak 2015), vascular damage, and death. The route should be clearly labeled as an absolute contraindication in harm reduction content.

### Contradictions Between Seed and Literature

- **Alcohol interaction:** Seed data = "unknown"; Literature = well-characterized pharmacokinetic interaction (see above). **This requires correction.**
- **Molecular data fields:** All blank in seed; confirmed from PubChem. Not a contradiction, just incomplete seed data.
- **No contradictions found** in dose ranges, duration data, or pharmacological class characterizations.

### Sections Relying on Structural Analogy

- Tolerance development rate and timing parameters (5-day half-life, 1.5-week reset) — structural analogy from stimulant class
- Cross-tolerance with dopaminergics — class inference
- MDMA interaction severity — pharmacological inference
- Oral bioavailability estimate (expected higher than MPH due to ethyl ester) — structural inference
- Human half-life (not established; likely 2–4h based on horse PK and MPH class data) — inference